

Primary Cells Market by Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Pharma Biotech, CROs, Academia), Region - Global Forecast to 2028

Market Report | 2023-07-06 | 217 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global primary cells market is projected to reach USD 2.8 billion by 2028 from USD 1.7 billion in 2023, at a CAGR of 10.5% during the forecast period. On the basis of origin, the primary cells market is divided into animal and human primary cells. In 2022, the human primary cells segment accounted for the largest share of the primary cells market. Human primary cells are used for the development of novel cancer therapies, for studying human cancerous cell models and toxicology studies, and in the cosmetic industry. The other key driving factors for the human primary cells market include the demand for accurate disease models, the rise of regenerative medicine, safety testing requirements, and technological innovations within the scientific community. "Hematopoietic cells segment accounted for the largest share in the primary cells market, by type in 2022." Based on type, the primary cells market is segmented into hematopoietic cells, dermatophytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells. In 2022, the hematopoietic cells segment accounted for the largest market share. Hematopoietic cell transplants are frequently and constantly used to develop novel cancer therapies to treat blood cancers and other disorders of the immune system. Hematopoietic cells are also used to understand the biochemical pathways of tumor cells and the efficacy of different drugs. As a result, this segment accounts for the largest market share of the market. "In 2022, the pharmaceutical & biotechnology companies, and CROs segment accounted for the largest share of the global primary cells market, by the end user." On the basis of end users, the primary cells market is segmented into pharmaceutical & biotechnology companies, and CROs, academic & research institutes, and other end users. In 2022, pharmaceutical & biotechnology companies and CROs accounted for the largest share of the primary cells market, mainly due to the high adoption of primary cells in cell-based experiments and cancer research in pharmaceutical & biotechnology companies

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

and CROs; and the increasing number of R&D facilities globally. "Asia Pacific, primary cells market, is expected to witness the highest growth during the forecast period." In 2022, North America accounted for the largest share of the primary cells market, followed by Europe. North America and Europe are the preferred locations for drug discovery due to established clusters in these regions, resulting in the largest market for primary cells. The Asia Pacific is projected to register the highest CAGR during the forecast period. Growth in this region is expected to be centered on China and Japan. Factors such as the presence of a large population and the rising incidence of cancer, increasing R&D spending on biopharmaceutical projects, and the growth of the biotechnology industry in developing countries are the major factors contributing to the growth of the Asia Pacific market are driving the growth of the primary cells market in this region. A breakdown of the primary participants referred to for this report is provided below: By Company: Tier 1 - 20%, Tier 2 - 45%, Tier 3- 35% By Designation: C-Level-30%, Directors - 20%, and Others - 50% By Region: North America-36%, Europe-25%, Asia Pacific-27%, RoW-12% The prominent players in the global primary cells market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), AllCells (US), American Type Culture Collection (ATCC), and Axol Bioscience Ltd. (UK), among others. Research Coverage: The report analyzes the primary cells market and aims to estimate the market size and future growth potential. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, product offerings, and recent developments. Reasons to Buy the Report

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall primary cells market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (Increasing cancer research, Advantages of primary human cells over cell lines, Increasing demand for monoclonal antibodies, Rapid growth in the biotechnology and biopharmaceutical industries, Growing focus on personalized medicine, Government investments for cell-based research), restraints (Concerns regarding primary cell culture contamination, Ethical concerns regarding research in cell biology), opportunities (Advancing biomedical research using primary cells in 3D cultures), and challenges (Sourcing and availability of primary cells) influencing the growth of the primary cells market
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the Primary Cells Market
- Market Development: Comprehensive information about lucrative markets - the report analyses the primary cells market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the primary cells market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Thermo Fisher Scientific Inc. (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), AllCells (US), American Type Culture Collection (ATCC), and Axol Bioscience Ltd. (UK).

Table of Contents:

- 1 INTRODUCTION 26
- 1.1 STUDY OBJECTIVES 26

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1.2	MARKET DEFINITION	26
1.2.1	INCLUSIONS & EXCLUSIONS	27
1.3	STUDY SCOPE	27
1.3.1	MARKETS COVERED	27
1.3.2	YEARS CONSIDERED	28
1.4	CURRENCY	28
1.5	LIMITATIONS	28
1.6	STAKEHOLDERS	29
1.7	SUMMARY OF CHANGES	29
1.8	RECESSION IMPACT	30
2	RESEARCH METHODOLOGY	31
2.1	RESEARCH DATA	31
	FIGURE 1 PRIMARY CELLS MARKET: RESEARCH DESIGN	31
2.1.1	SECONDARY RESEARCH	32
2.1.2	PRIMARY RESEARCH	33
	FIGURE 2 PRIMARY CELLS MARKET: BREAKDOWN OF PRIMARIES	33
2.2	MARKET SIZE ESTIMATION	34
	FIGURE 3 PRIMARY CELLS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022	34
	FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 - REVENUE SHARE ANALYSIS (2022)	35
	FIGURE 5 ILLUSTRATIVE EXAMPLE OF MERCK KGAA: REVENUE SHARE ANALYSIS (2022)	35
	FIGURE 6 KEY INDUSTRY INSIGHTS	36
2.3	GROWTH FORECAST	37
	FIGURE 7 PRIMARY CELLS MARKET: CAGR PROJECTIONS, 2023-2028	37
	FIGURE 8 PRIMARY CELLS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	38
2.4	MARKET BREAKDOWN AND DATA TRIANGULATION	39
	FIGURE 9 DATA TRIANGULATION METHODOLOGY	39
2.5	RESEARCH ASSUMPTIONS	40
2.6	RISK ANALYSIS	40
2.7	RECESSION IMPACT	40
	TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024-2028 (% GROWTH)	40
	TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)	41
	TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)	41
3	EXECUTIVE SUMMARY	42
	FIGURE 10 PRIMARY CELLS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)	42
	FIGURE 11 PRIMARY CELLS MARKET, BY ORIGIN, 2023 VS. 2028 (USD MILLION)	43
	FIGURE 12 PRIMARY CELLS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	43
	FIGURE 13 GEOGRAPHICAL SNAPSHOT OF PRIMARY CELLS MARKET	44
4	PREMIUM INSIGHTS	45
4.1	PRIMARY CELLS MARKET OVERVIEW	45
	FIGURE 14 GROWING GLOBAL INCIDENCE OF CANCER TO DRIVE MARKET GROWTH	45
4.2	NORTH AMERICA: PRIMARY CELLS MARKET, BY END USER AND COUNTRY (2022)	46
	FIGURE 15 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS DOMINATED NORTH AMERICAN PRIMARY CELLS MARKET IN 2022	46
4.3	PRIMARY CELLS MARKET SHARE, BY TYPE, 2023 VS. 2028	46
	FIGURE 16 HEMATOPOIETIC CELLS SEGMENT TO DOMINATE MARKET IN 2028	46
4.4	PRIMARY CELLS MARKET SHARE, BY ORIGIN, 2022	47
	FIGURE 17 HUMAN PRIMARY CELLS SEGMENT DOMINATED MARKET IN 2022	47

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.5	PRIMARY CELLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	47
FIGURE 18	ASIA PACIFIC COUNTRIES TO REGISTER HIGH GROWTH RATES FROM 2023 TO 2028	47
5	MARKET OVERVIEW	48
5.1	INTRODUCTION	48
5.2	MARKET DYNAMICS	48
FIGURE 19	PRIMARY CELLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	48
TABLE 4	PRIMARY CELLS MARKET: IMPACT ANALYSIS	49
5.2.1	DRIVERS	49
5.2.1.1	Increasing cancer research	49
TABLE 5	PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2020 VS. 2035	50
TABLE 6	ESTIMATED NUMBER OF NEW CASES OF ALL CANCERS (EXCLUDING NON-MELANOMA SKIN CANCER) FOR BOTH SEXES, 2020 VS. 2040	50
5.2.1.2	Advantages of primary human cells over cell lines	51
5.2.1.3	Increasing demand for monoclonal antibodies	52
5.2.1.4	Rapid growth in biotechnology and biopharmaceutical industries	52
FIGURE 20	GLOBAL PHARMACEUTICAL R&D SPENDING, 2014-2028	53
5.2.1.5	Growing focus on personalized medicine	53
TABLE 7	GROWTH IN NUMBER OF PERSONALIZED MEDICATIONS, 2015-2022	54
5.2.1.6	Government investments for cell-based research	54
5.2.2	RESTRAINTS	55
5.2.2.1	Concerns regarding primary cell culture contamination	55
5.2.2.2	Ethical concerns regarding research in cell biology	55
5.2.3	OPPORTUNITIES	56
5.2.3.1	Advancing biomedical research using primary cells in 3D cultures	56
5.2.4	CHALLENGES	56
5.2.4.1	Sourcing and availability of primary cells	56
5.3	REGULATORY ANALYSIS	57
5.3.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	57
5.4	PRICING ANALYSIS	58
TABLE 8	AVERAGE PRICE OF PRIMARY CELL PRODUCTS, BY KEY PLAYER (USD)	58
5.5	VALUE CHAIN ANALYSIS	59
FIGURE 21	MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE	60
5.6	SUPPLY CHAIN ANALYSIS	60
FIGURE 22	DISTRIBUTION-A STRATEGY PREFERRED BY PROMINENT COMPANIES	61
5.7	ECOSYSTEM ANALYSIS	62
FIGURE 23	ECOSYSTEM ANALYSIS OF PRIMARY CELLS MARKET	62
TABLE 9	PRIMARY CELLS MARKET ECOSYSTEM	63
5.8	KEY CONFERENCES & EVENTS, 2023-2024	64
TABLE 10	PRIMARY CELLS MARKET: LIST OF CONFERENCES & EVENTS	64
5.9	TECHNOLOGY ANALYSIS	64
5.10	PORTER'S FIVE FORCES ANALYSIS	65
TABLE 11	PRIMARY CELLS MARKET: PORTER'S FIVE FORCES ANALYSIS	65
5.10.1	THREAT OF NEW ENTRANTS	65
5.10.2	THREAT OF SUBSTITUTES	65
5.10.3	BARGAINING POWER OF SUPPLIERS	65
5.10.4	BARGAINING POWER OF BUYERS	66
5.10.5	INTENSITY OF COMPETITIVE RIVALRY	66

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.11	KEY STAKEHOLDERS & BUYING CRITERIA	66
5.11.1	KEY STAKEHOLDERS IN BUYING PROCESS	66
FIGURE 24	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRIMARY CELL PRODUCTS	66
5.11.2	BUYING CRITERIA FOR PRIMARY CELLS	67
FIGURE 25	KEY BUYING CRITERIA FOR END USERS	67
6	PRIMARY CELLS MARKET, BY TYPE	68
6.1	INTRODUCTION	69
TABLE 12	PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION)	69
6.2	HEMATOPOIETIC CELLS	70
6.2.1	INCREASING CANCER RESEARCH & FUNDING TO PROPEL MARKET GROWTH	70
TABLE 13	TYPES OF HEMATOPOIETIC CELLS	70
TABLE 14	HEMATOPOIETIC CELLS MARKET, BY REGION, 2021-2028 (USD MILLION)	70
TABLE 15	NORTH AMERICA: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	71
TABLE 16	EUROPE: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	71
TABLE 17	ASIA PACIFIC: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	71
6.3	DERMATOCYTES	72
6.3.1	RISING PREVALENCE OF MELANOMA TO BOOST DEMAND	72
TABLE 18	DERMATOCYTES MARKET, BY REGION, 2021-2028 (USD MILLION)	72
TABLE 19	NORTH AMERICA: DERMATOCYTES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	73
TABLE 20	EUROPE: DERMATOCYTES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	73
TABLE 21	ASIA PACIFIC: DERMATOCYTES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	73
6.4	GASTROINTESTINAL CELLS	74
6.4.1	GROWING INCIDENCE OF STOMACH CANCER TO BOLSTER GROWTH	74
TABLE 22	GASTROINTESTINAL CELLS MARKET, BY REGION, 2021-2028 (USD MILLION)	74
TABLE 23	NORTH AMERICA: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	74
TABLE 24	EUROPE: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	75
TABLE 25	ASIA PACIFIC: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	75
6.5	HEPATOCYTES	75
TABLE 26	GLOBAL LIVER DISORDER INCIDENCE	76
TABLE 27	HEPATOCYTES MARKET, BY REGION, 2021-2028 (USD MILLION)	77
TABLE 28	NORTH AMERICA: HEPATOCYTES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	77
TABLE 29	EUROPE: HEPATOCYTES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	77
TABLE 30	ASIA PACIFIC: HEPATOCYTES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	78
TABLE 31	HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION)	78
6.5.1	CRYOPRESERVED HEPATOCYTES	78
6.5.1.1	Longer lifespan of cryopreserved hepatocytes than fresh hepatocytes to drive market growth	78
TABLE 32	CRYOPRESERVED HEPATOCYTES MARKET, BY REGION, 2021-2028 (USD MILLION)	79
TABLE 33	NORTH AMERICA: CRYOPRESERVED HEPATOCYTES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	79
TABLE 34	EUROPE: CRYOPRESERVED HEPATOCYTES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	79
TABLE 35	ASIA PACIFIC CRYOPRESERVED HEPATOCYTES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	80
6.5.2	FRESH HEPATOCYTES	80
6.5.2.1	Stringent regulations and limited availability of fresh hepatocytes to limit market growth	80
TABLE 36	FRESH HEPATOCYTES MARKET, BY REGION, 2021-2028 (USD MILLION)	80
TABLE 37	NORTH AMERICA: FRESH HEPATOCYTES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	81
TABLE 38	EUROPE: FRESH HEPATOCYTES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	81
TABLE 39	ASIA PACIFIC: FRESH HEPATOCYTES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	81
6.6	LUNG CELLS	82

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.6.1	INCREASING RATE OF LUNG CANCER & COPD TO DRIVE DEMAND FOR LUNG CELLS	82
TABLE 40	LUNG CELLS MARKET, BY REGION, 2021-2028 (USD MILLION)	82
TABLE 41	NORTH AMERICA: LUNG CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	83
TABLE 42	EUROPE: LUNG CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	83
TABLE 43	ASIA PACIFIC: LUNG CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	83
6.7	RENAL CELLS	84
6.7.1	LACK OF AVAILABILITY OF EFFECTIVE RENAL THERAPIES TO PROPEL MARKET GROWTH	84
TABLE 44	RENAL CELLS MARKET, BY REGION, 2021-2028 (USD MILLION)	84
TABLE 45	NORTH AMERICA: RENAL CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	84
TABLE 46	EUROPE: RENAL CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	85
TABLE 47	ASIA PACIFIC: RENAL CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	85
6.8	HEART CELLS	85
6.8.1	HIGH INCIDENCE OF CARDIOVASCULAR DISEASES TO SUPPORT GROWTH	85
TABLE 48	HEART CELLS MARKET, BY REGION, 2021-2028 (USD MILLION)	86
TABLE 49	NORTH AMERICA: HEART CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	86
TABLE 50	EUROPE: HEART CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	86
TABLE 51	ASIA PACIFIC: HEART CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	87
6.9	MUSCULOSKELETAL CELLS	87
6.9.1	RISING INCIDENCE OF MUSCULOSKELETAL DISORDERS TO PROPEL MARKET GROWTH	87
TABLE 52	MUSCULOSKELETAL CELLS MARKET, BY REGION, 2021-2028 (USD MILLION)	88
TABLE 53	NORTH AMERICA: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	88
TABLE 54	EUROPE: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	88
TABLE 55	ASIA PACIFIC: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	89
6.10	OTHER PRIMARY CELLS	89
TABLE 56	OTHER PRIMARY CELLS MARKET, BY REGION, 2021-2028 (USD MILLION)	89
TABLE 57	NORTH AMERICA: OTHER PRIMARY CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	90
TABLE 58	EUROPE: OTHER PRIMARY CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	90
TABLE 59	ASIA PACIFIC: OTHER PRIMARY CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	90
7	PRIMARY CELLS MARKET, BY ORIGIN	91
7.1	INTRODUCTION	92
TABLE 60	PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION)	92
7.2	HUMAN PRIMARY CELLS	92
7.2.1	INCREASING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH	92
TABLE 61	HUMAN PRIMARY CELLS MARKET, BY REGION, 2021-2028 (USD MILLION)	93
TABLE 62	NORTH AMERICA: HUMAN PRIMARY CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	93
TABLE 63	EUROPE: HUMAN PRIMARY CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	94
TABLE 64	ASIA PACIFIC: HUMAN PRIMARY CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	94
7.3	ANIMAL PRIMARY CELLS	94
7.3.1	RISING INVESTMENTS IN ANIMAL CELL RESEARCH TO PROPEL MARKET GROWTH	94
TABLE 65	ANIMAL PRIMARY CELLS MARKET, BY REGION, 2021-2028 (USD MILLION)	95
TABLE 66	NORTH AMERICA: ANIMAL PRIMARY CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	95
TABLE 67	EUROPE: ANIMAL PRIMARY CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	96
TABLE 68	ASIA PACIFIC: ANIMAL PRIMARY CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	96
8	PRIMARY CELLS MARKET, BY END USER	97
8.1	INTRODUCTION	98
TABLE 69	PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION)	98
8.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS	98

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.2.1 INCREASING INVESTMENTS IN CELL-BASED RESEARCH TO DRIVE MARKET GROWTH 98

TABLE 70 PRIMARY CELLS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2021-2028 (USD MILLION) 99

TABLE 71 NORTH AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2021-2028 (USD MILLION) 99

TABLE 72 EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2021-2028 (USD MILLION) 99

TABLE 73 ASIA PACIFIC: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2021-2028 (USD MILLION) 100

8.3 ACADEMIC & RESEARCH INSTITUTES 100

8.3.1 INCREASING GOVERNMENT FUNDING FOR RESEARCH AND HIGH PREVALENCE OF CANCER TO FAVOR MARKET GROWTH 100

TABLE 74 PRIMARY CELLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION) 101

TABLE 75 NORTH AMERICA: PRIMARY CELLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 101

TABLE 76 EUROPE: PRIMARY CELLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 101

TABLE 77 ASIA PACIFIC: PRIMARY CELLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 102

8.4 OTHER END USERS 102

TABLE 78 PRIMARY CELLS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION) 102

TABLE 79 NORTH AMERICA: PRIMARY CELLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 103

TABLE 80 EUROPE: PRIMARY CELLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 103

TABLE 81 ASIA PACIFIC: PRIMARY CELLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 103

9 PRIMARY CELLS MARKET, BY REGION 104

9.1 INTRODUCTION 105

TABLE 82 PRIMARY CELLS MARKET, BY REGION, 2021-2028 (USD MILLION) 105

9.2 NORTH AMERICA 105

FIGURE 26 NORTH AMERICA: PRIMARY CELLS MARKET SNAPSHOT 106

TABLE 83 NORTH AMERICA: PRIMARY CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 106

TABLE 84 NORTH AMERICA: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION) 107

TABLE 85 NORTH AMERICA: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION) 107

TABLE 86 NORTH AMERICA: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION) 108

TABLE 87 NORTH AMERICA: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION) 108

9.2.1 US 108

9.2.1.1 High R&D spending and growing support for stem cell research to drive market growth 108

TABLE 88 US: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION) 109

TABLE 89 US: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION) 110

TABLE 90 US: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION) 110

TABLE 91 US: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION) 111

9.2.2 CANADA 111

9.2.2.1 Presence of advanced R&D infrastructure to boost market 111

TABLE 92 CANADA: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION) 112

TABLE 93 CANADA: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION) 112

TABLE 94 CANADA: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION) 113

TABLE 95 CANADA: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION) 113

9.2.3 NORTH AMERICA: IMPACT OF RECESSION 113

9.3 EUROPE 114

TABLE 96 EUROPE: PRIMARY CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 114

TABLE 97 EUROPE: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION) 114

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 98□EUROPE: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION)□115

TABLE 99□EUROPE: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION)□115

TABLE 100□EUROPE: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION)□116

9.3.1□UK□116

9.3.1.1□Growth in life science industry to fuel market growth□116

TABLE 101□UK: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION)□117

TABLE 102□UK: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION)□117

TABLE 103□UK: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION)□118

TABLE 104□UK: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION)□118

9.3.2□GERMANY□118

9.3.2.1□Increasing life science research activities to support market growth□118

TABLE 105□GERMANY: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION)□119

TABLE 106□GERMANY: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION)□119

TABLE 107□GERMANY: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION)□120

TABLE 108□GERMANY: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION)□120

9.3.3□FRANCE□120

9.3.3.1□Robust biotechnology infrastructure to support growth□120

TABLE 109□FRANCE: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION)□121

TABLE 110□FRANCE: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION)□122

TABLE 111□FRANCE: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION)□122

TABLE 112□FRANCE: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION)□123

9.3.4□ITALY□123

9.3.4.1□Increasing number of cell biology seminars and conferences to fuel adoption of primary cells□123

TABLE 113□ITALY: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION)□124

TABLE 114□ITALY: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION)□124

TABLE 115□ITALY: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION)□125

TABLE 116□ITALY: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION)□125

9.3.5□REST OF EUROPE□125

TABLE 117□REST OF EUROPE: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION)□126

TABLE 118□REST OF EUROPE: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION)□126

TABLE 119□REST OF EUROPE: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION)□127

TABLE 120□REST OF EUROPE: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION)□127

9.3.6□EUROPE: IMPACT OF RECESSION□128

9.4□ASIA PACIFIC□128

FIGURE 27□ASIA PACIFIC: PRIMARY CELLS MARKET SNAPSHOT□129

TABLE 121□ASIA PACIFIC: PRIMARY CELLS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)□129

TABLE 122□ASIA PACIFIC: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION)□130

TABLE 123□ASIA PACIFIC: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION)□130

TABLE 124□ASIA PACIFIC: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION)□131

TABLE 125□ASIA PACIFIC: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION)□131

9.4.1□CHINA□131

9.4.1.1□Growing focus on cancer therapeutics-related research to bolster growth□131

TABLE 126□CHINA: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION)□132

TABLE 127□CHINA: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION)□132

TABLE 128□CHINA: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION)□133

TABLE 129□CHINA: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION)□133

9.4.2□JAPAN□133

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.4.2.1	Government initiatives to propel market growth in Japan	133
TABLE 130	JAPAN: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION)	134
TABLE 131	JAPAN: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION)	134
TABLE 132	JAPAN: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION)	135
TABLE 133	JAPAN: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION)	135
9.4.3	REST OF ASIA PACIFIC	135
TABLE 134	REST OF ASIA PACIFIC: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION)	136
TABLE 135	REST OF ASIA PACIFIC: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION)	136
TABLE 136	REST OF ASIA PACIFIC: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION)	137
TABLE 137	REST OF ASIA PACIFIC: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION)	137
9.4.4	ASIA PACIFIC: IMPACT OF RECESSION	137
9.5	REST OF THE WORLD	138
TABLE 138	REST OF THE WORLD: PRIMARY CELLS MARKET, BY ORIGIN, 2021-2028 (USD MILLION)	139
TABLE 139	REST OF THE WORLD: PRIMARY CELLS MARKET, BY TYPE, 2021-2028 (USD MILLION)	139
TABLE 140	REST OF THE WORLD: HEPATOCYTES MARKET, BY TYPE, 2021-2028 (USD MILLION)	140
TABLE 141	REST OF THE WORLD: PRIMARY CELLS MARKET, BY END USER, 2021-2028 (USD MILLION)	140
9.5.1	REST OF THE WORLD: IMPACT OF RECESSION	141
10	COMPETITIVE LANDSCAPE	142
10.1	INTRODUCTION	142
10.2	RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS	142
FIGURE 28	PRIMARY CELLS MARKET: STRATEGIES ADOPTED	142
10.3	REVENUE SHARE ANALYSIS	143
FIGURE 29	REVENUE ANALYSIS OF KEY PLAYERS (2019-2022)	143
10.4	MARKET SHARE ANALYSIS	143
FIGURE 30	MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)	144
TABLE 142	PRIMARY CELLS MARKET: DEGREE OF COMPETITION	144
10.5	COMPANY EVALUATION QUADRANT	145
FIGURE 31	PRIMARY CELLS MARKET: COMPANY EVALUATION MATRIX, 2022	146
10.5.1	STARS	146
10.5.2	EMERGING LEADERS	146
10.5.3	PERVASIVE PLAYERS	147
10.5.4	PARTICIPANTS	147
10.6	COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS	147
10.6.1	PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES)	147
TABLE 143	PRIMARY CELLS MARKET: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS	147
10.6.2	REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)	148
TABLE 144	PRIMARY CELLS MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS	148
10.7	COMPANY EVALUATION QUADRANT: START-UPS/SMES	149
FIGURE 32	PRIMARY CELLS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022	149
10.7.1	PROGRESSIVE COMPANIES	150
10.7.2	STARTING BLOCKS	150
10.7.3	RESPONSIVE COMPANIES	150
10.7.4	DYNAMIC COMPANIES	150
10.8	COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS	150
TABLE 145	PRIMARY CELLS MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS	150
TABLE 146	PRIMARY CELLS MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS	152
10.9	COMPETITIVE SCENARIO AND TRENDS	152

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.9.1 PRODUCT LAUNCHES 152

TABLE 147 PRIMARY CELLS MARKET: PRODUCT LAUNCHES, JANUARY 2020-JUNE 2023 153

10.9.2 DEALS 153

TABLE 148 PRIMARY CELLS MARKET: DEALS, JANUARY 2020-JUNE 2023 153

10.9.3 OTHER DEVELOPMENTS 154

TABLE 149 PRIMARY CELLS MARKET: OTHER DEVELOPMENTS, JANUARY 2020-JUNE 2023 154

?

11 COMPANY PROFILES 155

11.1 MAJOR PLAYERS 155

(Business overview, Products offered, Recent Developments, MNM view)*

11.1.1 THERMO FISHER SCIENTIFIC, INC. 155

TABLE 150 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 155

FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 156

11.1.2 MERCK KGAA 159

TABLE 151 MERCK KGAA: COMPANY OVERVIEW 159

FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2022) 160

TABLE 152 OTHER DEVELOPMENTS 161

11.1.3 CORNING INCORPORATED 163

TABLE 153 CORNING INCORPORATED: BUSINESS OVERVIEW 163

FIGURE 35 CORNING INCORPORATED: COMPANY SNAPSHOT (2022) 164

11.1.4 LONZA GROUP 166

TABLE 154 LONZA GROUP: BUSINESS OVERVIEW 166

FIGURE 36 LONZA GROUP: COMPANY SNAPSHOT (2022) 167

TABLE 155 PRODUCT LAUNCHES 169

11.1.5 CHARLES RIVER LABORATORIES, INC. 170

TABLE 156 CHARLES RIVER LABORATORIES, INC.: BUSINESS OVERVIEW 170

FIGURE 37 CHARLES RIVER LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 171

TABLE 157 ACQUISITIONS 172

11.1.6 PROMOCCELL GMBH 173

TABLE 158 PROMOCCELL GMBH: BUSINESS OVERVIEW 173

TABLE 159 PRODUCT LAUNCHES 174

11.1.7 AMERICAN TYPE CULTURE COLLECTION (ATCC) 175

TABLE 160 AMERICAN TYPE CULTURE COLLECTION (ATCC): BUSINESS OVERVIEW 175

11.1.8 CELL BIOLOGICS, INC. 180

TABLE 161 CELL BIOLOGICS, INC.: BUSINESS OVERVIEW 180

11.1.9 ZENBIO, INC. 185

TABLE 162 ZENBIO, INC.: BUSINESS OVERVIEW 185

11.1.10 STEMCELL TECHNOLOGIES, INC. 187

TABLE 163 STEMCELL TECHNOLOGIES, INC.: BUSINESS OVERVIEW 187

11.1.11 ALLCELLS 193

TABLE 164 ALLCELLS: BUSINESS OVERVIEW 193

11.1.12 IXCELLS BIOTECHNOLOGIES 194

TABLE 165 IXCELLS BIOTECHNOLOGIES: BUSINESS OVERVIEW 194

TABLE 166 AGREEMENTS 200

11.1.13 NEUROMICS 201

TABLE 167 NEUROMICS: BUSINESS OVERVIEW 201

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

companies.

11.2 OTHER COMPANIES 202

11.2.1 AXOL BIOSCIENCE LTD. 202

TABLE 168 AXOL BIOSCIENCE LTD.: COMPANY OVERVIEW 202

11.2.2 STEMEXPRESS 203

TABLE 169 STEMEXPRESS: COMPANY OVERVIEW 203

11.2.3 BIOIVT 204

TABLE 170 BIOIVT: COMPANY OVERVIEW 204

11.2.4 SCIENCELL RESEARCH LABORATORIES, INC. 205

TABLE 171 SCIENCELL RESEARCH LABORATORIES, INC.: COMPANY OVERVIEW 205

11.2.5 AMSBIO 207

TABLE 172 AMSBIO: COMPANY OVERVIEW 207

11.2.6 PROMAB BIOTECHNOLOGIES, INC. 208

TABLE 173 PROMAB BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW 208

11.2.7 CREATIVE BIOARRAY 209

TABLE 174 CREATIVE BIOARRAY: COMPANY OVERVIEW 209

11.2.8 BPS BIOSCIENCE, INC. 211

TABLE 175 BPS BIOSCIENCE, INC.: COMPANY OVERVIEW 211

11.2.9 EPITHELIX 212

TABLE 176 EPITHELIX: COMPANY OVERVIEW 212

11.2.10 REACHBIO RESEARCH LABS 213

TABLE 177 REACHBIO RESEARCH LABS: COMPANY OVERVIEW 213

11.2.11 ACCEGEN 214

TABLE 178 ACCEGEN: COMPANY OVERVIEW 214

11.2.12 KOSHEEKA 215

TABLE 179 KOSHEEKA: COMPANY OVERVIEW 215

12 APPENDIX 216

12.1 DISCUSSION GUIDE 216

12.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL 219

12.3 CUSTOMIZATION OPTIONS 221

12.4 RELATED REPORTS 221

12.5 AUTHOR DETAILS 222

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Primary Cells Market by Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Pharma Biotech, CROs, Academia), Region - Global Forecast to 2028

Market Report | 2023-07-06 | 217 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scottis-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scottis-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scottis-international.com

www.scottis-international.com

Zip Code*

Country*

Date

2026-03-03

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com